N/A N=10 Acupuncture Study on Rheumatoid Arthritis, Monitoring Microbiome and Blood
Rheumatoid Arthritis
Primary: ACR20 Response Rate at 3 Weeks — 0; 1 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=6 Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-248
Healthy
Primary: Number of Treatment Related Adverse Events — 3; 4; 0; 3 Number of events
Phase 3 N=63 A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents
Cerebral Palsy, Dyskinetic
Primary: Change From Baseline in the Movement Disorder-Childhood Rating Scale (MD-CRS) Part II Total Score (Movement Disorder Severity, Centrally Read) at Week 15 — -0.4; -1.5…
N/A N=40 Use of Interferential Current (IFC) Therapy After Total Knee Arthroplasty
Osteo Arthritis Knee
Primary: Post-operative Opioid Pain Medication Usage — 24.5; 15.0 MME
Phase 2 N=97 ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma, Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer
Soft Tissue Sarcoma
Primary: Progression-free Survival (PFS) (Cohort 1 Only) — 5.0597 months
Phase 3 N=483 Long-Term Study of EN3835 (CCH-aaes) in Edematous Fibrosclerotic Panniculopathy (Cellulite)
Edematous Fibrosclerotic Panniculopathy · Cellulite
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 58; 29; 43; 45 Participants
N/A N=144 Effects of Transcutaneous Electrical Nerve Stimulation on Chemotherapy-Induced Peripheral Neuropathy
Chemotherapy-Induced Peripheral Neuropathy
Primary: Chemotherapy-induced Peripheral Neuropathy (CIPN) Symptoms — 32.32; 33.37 score on a scale — p=0.199
Phase 2 N=44 Comparison Of Rocuronium Reversal By Sugammadex To Succinylcholine For Electroconvulsive Therapy (ECT)
Neuromuscular Blockade
Primary: Recovery Time of T1 to 90% Baseline — 6.79; 10.97 minutes
N/A N=24 taVNS Cold Pressor
taVNS · Brain Stimulation
Primary: Mean Heart Rate (Before CPT/taVNS) — 72.86; 72.0 beats per minute
Early Phase 1 N=62 Responses to E-Cigarette Advertising
E-Cig Use
Primary: Attention to Specific ad Feature — -1.7062; -0.9676; -1.8238 Beats per minute
Phase 3 N=98 Obesity and Asthma: Nutrigenetic Response to Omega-3 Fatty Acids
Asthma · Obesity
Primary: Asthma Control Questionnaire (Juniper) — 1.13; 1.08; -0.08; -0.09 score on a scale — p=0.05
N/A N=2,108 Worksite Lifestyle Program for Reducing Diabetes and Cardiovascular Risk in India
Diabetes · Heart Disease · Obesity
Primary: Number of Participants Reaching Two or More Cardiometabolic Risk Goals — 485; 351 Participants
N/A N=271 Promoting Breast Cancer Screening in Women Who Survived Childhood Cancer
Breast Neoplasms · Early Detection of Cancer
Primary: Percentage of Women Who Completed a Breast MRI and Mammogram — 8.9; 22.0; 17.8 percentage of participants — p=0.019
Phase 3 N=40 The EVARREST® Paediatric Mild/Moderate Liver and Soft Tissue Bleeding Study
Hemorrhage · Soft Tissue Bleeding · Hepatic Parenchyma Bleeding
Primary: Absolute Time to Haemostasis (TTH) — 4.0; 4.0 Minutes
N/A N=102 Impact of Acetaminophen on Performance of Guardian™ Sensor (3) in Adults
Type 1 Diabetes Mellitus · Type 2 Diabetes Mellitus
Primary: Bias (mg/dL) Between the Guardian™ Sensor (3) Values and Yellow Springs Instrument™ (YSI™) Plasma Glucose — -0.46; 0.86; -4.78; -4.45 mg/dL